WARSAW, POLAND - May 19, 2014 - Warsaw - 19 May 2014 - Dr. Yafit Stark, Vice President, Global Clinical Advisor at Teva, a leading global generic and specialty pharmaceutical company, will join the upcoming BioForum 2014 as a keynote speaker on a special invitation of KCR, European Contract Research Organization (CRO). BioForum is a major biotechnological conference in Central and Eastern Europe (CEE) and it will take place on 28-29 May 2014 in Lodz, Poland.

"Today the CEE region plays a significant role in many clinical trial strategies for many companies. The medical and research infrastructure is ideally suited for clinical drug development," said Dr. Yafit Stark.

KCR President & CEO, Mike Jagielski, adds: "The CEE region draws international pharma companies' attention thanks to its cost-effectiveness and excellent medical standards. Additionally, focusing on new technologies and processes will optimize conducting clinical research and raise trials' efficiency. KCR's successful growth in the CEE region and our expansion to Western Europe is a great example that providing high quality services can result in creating a win-win relationship between Pharma/Biotech and CRO. However, becoming a 'first choice' location to host clinical studies still requires changing limited perception about the CEE region. The newly emerging regional biotechnology sector will definitely help raising the CEE picture."

KCR is pleased to welcome Dr. Stark as an honored guest at BioForum. She has been a pioneer in global clinical research and established the Innovative Research & Development (R&D) Division of Teva in the U.S. She was also responsible for the clinical development program of several successful innovative products, such as the blockbuster MS therapy, Copaxone. "Innovation is the lifeblood of biotechnology. The Israeli model, supporting innovation through incubators, has proven itself to be highly successful, and represents a model approach for other regions," adds Dr. Stark.

Dr. Stark's BioForum keynote speech on "Innovations vs Stagnation: Challenges and Opportunities for the Bio and Medical Communities" will take place on 29 May 2014.

KCR's top representatives, Mike Jagielski, CEO, Anna Baran, VP and Chief Medical Officer, and Marek Kiecana, Chairman of KCR's Supervisory Board will also be present on BioForum. The KCR's panel entitled "Advantages of Execution of Bio-similar and Bio-equivalent Studies in the CEE Region" will be held on the first day of the event. For full information on BioForum please visit: http://www.bioforum.pl/.

If you would like to learn more about KCR services and operations, or speak to KCR top representatives directly, please contact Joanna Lewandowska, PR & Marketing Manager, at joanna.lewandowska@kcrcro.com. Please include your full contact details in the query.

About KCR

KCR is a European Contract Research Organization (CRO) and a strategic solutions provider for companies who are looking for a reliable alternative to global CROs. Almost 300 professionals operating across 18 countries in Europe as well as the U.S. offer full service capabilities for Phase I-IV Clinical Development Projects across a wide range of therapeutic areas. KCR also operates as a Functional Service Provider with strategic and tactical solutions in Clinical Operations, Data Management and Expert Sourcing. Our service portfolio includes delivery of regional and local Post-Marketing Clinical Services according to the clients' needs. KCR supports 12 of the Top 20 Global Pharma companies with its services on long standing global or local contracts.

For more information please visit:www.kcrcro.com.

Contact:

Joanna Lewandowska

PR & Marketing Manager

KCR

P: +48 605 053 164

Email: joanna.lewandowska@kcrcro.com

www.kcrcro.com